HomeLatestBiotech Stocks are Suffering from Tax Loss Harvesting
Biotech Stocks are Suffering from Tax Loss Harvesting
December 01, 2021 - by Kevin Flynn
Tis the season to be jolly, unless of course you own biotech stock. Your December is going to be a rough ride, but not for the reasons you might think. Those shares you’re thinking about dumping could be some of your biggest earners next year. December is gift-giving season. Harvest your losses to prepare for tax season, then get ready to start buying.
Bloomberg released an article last week about Cathie Wood’s Genomics Fund being down 27% YTD. That number has climbed to 31% since the piece was published. The fund, called ARK Genomic Revolution (ARKG), is an ETF that focuses on AI in health care. Who wouldn’t want to invest in that? Based on the $520 million in November outflows, investors are wavering.
Tax Loss Harvesting Creates Opportunities
As most of my readers know, I’m not really a fan of biotech stocks. In the best of times, they’re volatile and unpredictable. Despite those misgivings, I am tempted to pick up some bargain basement deals this month. Investors are selling funds like ARK because they’re the biggest losers this year. Declaring those losses minimizes tax liability. It’s good business.
Investors sell. Share prices fall. Buyers get a holiday gift. Take Teledoc Health Inc (TDOC) as an example. It dropped 33% last month and has shed more than $100 per share this year, but cash flow is strong, and the company continues to generate growth in telehealth visits. Sales growth is projected at 30% annually for the next few years. I think that’s worth buying.
Teledoc is one of the holdings in the ARK fund. So is Exact Sciences Corporation (EXAS). They’re down 34% for the year, so they are a prime candidate for tax loss harvesting. Dig a little deeper and you’ll find that those losses could be attributed to Pfizer basically abandoning them on the sale of Cologuard. That partnership ended on 11/30. I bought EXAS this morning.
I have a set routine this time of year that I’m happy to share with you. Every holding I harvest goes on a watch list. In two weeks, I’ll review that list and start buying again. Doing it right before Christmas is like meeting Santa Claus in my living room. The gifts are scattered under the tree. I just need to pick them up and unwrap them.
Is it Time to Sell Your Vaccine Stocks?
Let’s look at the opposite side of the coin. Moderna (MRNA) is up 193% this year. They opened at $329 this morning, but share prices peaked at $484 back in August. Have you held it too long? The battle for first place in the vaccine race ended a while ago and has turned into a three-way cold war. Moderna will not emerge victorious. Dump it and call it a day.
Pfizer (PFE) is another story. They’re showing a modest gain this year (46%) by pharmaceutical standards, but they’re up 79.67% over the past five years. That’s rare longevity in this space. Pfizer is diversified, has an active development pipeline, and will be the dominant player in the Covid vaccine space. You can take that to the bank.
I refuse to invest in Johnson & Johnson (JNJ) for ethical reasons. Read into that what you will. They’re a distant third in the vaccine race anyway. If I did own them, I’d sell my shares right now and buy Novo Nordisk (NVO), an ESG company that makes insulin, not vaccines. They’re up 51% this year and are on a five-year uptrend. Now that’s a solid pharma investment.
Share this article:
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
This communication was produced by Prism MarketView, “PRISM”. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
“PRISM” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PRISM” engage in any activities that would require such registrations. “PRISM” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
This communication may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, market conditions, regulatory developments, and other factors beyond the control of the profiled company. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. PRISM undertakes no obligation to update or revise any such statements.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PRISM” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PRISM”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PRISM” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
Key Points Barclays launched coverage of 20 aerospace and defense companies with a broadly positive view of the sector. Boeing,…
About the Author:
Kevin Flynn
A former financial professional and founder of AdvisorScale Financial Writing, Kevin lives in Leominster, Massachusetts with his wife Evelyn, two cats, and nine wonderful grandchildren.
